AveXis (AVXS) Given a $122.00 Price Target by UBS Group Analysts
UBS Group set a $122.00 target price on AveXis (NASDAQ:AVXS) in a report published on Friday morning, www.tipranks.com reports. The firm currently has a buy rating on the stock.
AVXS has been the topic of a number of other reports. Royal Bank of Canada reiterated a hold rating and set a $92.00 target price on shares of AveXis in a research report on Thursday, November 2nd. Canaccord Genuity began coverage on shares of AveXis in a research report on Thursday, October 26th. They set a hold rating and a $110.00 target price on the stock. Zacks Investment Research lowered shares of AveXis from a buy rating to a hold rating in a research report on Monday, October 30th. BidaskClub upgraded shares of AveXis from a sell rating to a hold rating in a research report on Thursday, December 21st. Finally, Citigroup upped their target price on shares of AveXis from $100.00 to $116.00 and gave the stock a buy rating in a research report on Monday, October 2nd. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have issued a buy rating to the stock. AveXis has an average rating of Buy and an average target price of $111.94.
AveXis (AVXS) traded down $2.66 during trading hours on Friday, reaching $102.08. 837,600 shares of the company’s stock were exchanged, compared to its average volume of 502,150. The firm has a market capitalization of $3,264.15, a price-to-earnings ratio of -18.29 and a beta of 2.46. AveXis has a 52-week low of $50.56 and a 52-week high of $116.15.
AveXis (NASDAQ:AVXS) last announced its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same period in the prior year, the business posted ($0.87) EPS. equities research analysts anticipate that AveXis will post -6.23 earnings per share for the current year.
In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $101.26, for a total value of $180,242.80. Following the completion of the sale, the vice president now owns 1,780 shares of the company’s stock, valued at $180,242.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $101.23, for a total transaction of $1,518,450.00. Following the completion of the sale, the insider now directly owns 1,841,019 shares of the company’s stock, valued at approximately $186,366,353.37. The disclosure for this sale can be found here. Over the last three months, insiders have sold 52,340 shares of company stock valued at $5,318,845. 18.60% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the business. Strs Ohio bought a new stake in AveXis in the third quarter valued at approximately $116,000. Ameritas Investment Partners Inc. increased its stake in AveXis by 331.0% in the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after purchasing an additional 1,622 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in AveXis by 688.6% in the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after purchasing an additional 1,577 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in AveXis in the third quarter valued at approximately $200,000. Finally, Deschutes Portfolio Strategy LLC bought a new stake in AveXis in the third quarter valued at approximately $203,000. 92.88% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/avexis-avxs-given-a-122-00-price-target-by-ubs-group-analysts/1798582.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with Analyst Ratings Network's FREE daily email newsletter.